Pharmafile Logo
Pharmafocus logo
Advanced Search

Eli Lilly

Showing 15 posts of 212 posts found.

pills_spill

Eli Lilly shares data from two phase 3 tirzepatide studies

July 28, 2023
Research and Development Eli Lilly, Obesity, clinical trial, tirzepatide, weight loss

Eli Lilly has announced results from its two phase 3 tirezepatide studies in adult patients with obesity or who are …

News
alzheimers_brain

Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

July 18, 2023
Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …

News

Eli Lilly to acquire Versanis Bio for $1.9bn

July 17, 2023
Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …

News
hal-gatewood-_jbclosdsd4-unsplash

Eli Lilly to acquire Sigilon Therapeutics

June 30, 2023
Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition

Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …

News

Eli Lilly to acquire DICE Therapeutics for immunology innovations

June 21, 2023
Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology

Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023
Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …

News

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023
Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …

News
lilly_entrance_web

Eli Lilly’s Type 2 diabetes drug outperforms semaglutide in trials

June 28, 2021
Sales and Marketing Eli Lilly, semaglutide, type 2 diabetes

Eli Lilly has announced that the SURPASS-2 clinical trial has shown tirzepatide achieved superior HbA1C and body weight reductions compared …

News

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

June 25, 2021
Medical Communications Alzheimer's, Eli Lilly, FDA

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing plans on Thursday to file …

News

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021
Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …

News

Eli Lilly and MiNA Therapeutics to collaborate on saRNA research

May 12, 2021
Research and Development Eli Lilly

Eli Lilly and MiNA Therapeutics have announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small …

News
lilly_entrance_web

Eli Lilly to collaborate with diabetes tech companies on insulin pen

May 10, 2021
Sales and Marketing Eli Lilly, diabetes

Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the …

News
Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

April 19, 2021
Sales and Marketing COVID-19, Eli Lilly, FDA, covid-19 treatment, lilly, pharma, pharma news

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the treatment of COVID-19, per the …

News
Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

March 17, 2021
Research and Development Eli Lilly, Phase III trial, lilly, mirikizumab, ulcerative colitis

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and all key secondary endpoints in …

News
Eli Lilly building

Eli Lilly’s COVID-19 treatment combination 87% effective in Phase III trial

March 11, 2021
COVID-19, Eli Lilly, covid-19 treatment

Eli Lilly has shown positive results in its Phase III combination drug trial, which reduced hospitalisations and deaths related to …

News

Latest content

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024

Innate Pharma shares results from phase 1/2 trial for blood cancer treatment

June 17, 2024

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024

AbbVie and FutureGen announce license agreement for IBD therapy

June 14, 2024

Pfizer shares update on DMD gene therapy clinical trial

June 13, 2024